

# Ikuo Hirano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1287588/publications.pdf>

Version: 2024-02-01

185  
papers

15,932  
citations

34016

52  
h-index

16605

123  
g-index

192  
all docs

192  
docs citations

192  
times ranked

5584  
citing authors

#	ARTICLE	IF	CITATIONS
1	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	1.5	1,839
2	ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). <i>American Journal of Gastroenterology</i> , 2013, 108, 679-692.	0.2	983
3	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	0.6	712
4	The Enteric Nervous System. <i>New England Journal of Medicine</i> , 1996, 334, 1106-1115.	13.9	708
5	Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. <i>Gut</i> , 2013, 62, 489-495.	6.1	671
6	Elimination Diet Effectively Treats Eosinophilic Esophagitis in Adults; Food Reintroduction Identifies Causative Factors. <i>Gastroenterology</i> , 2012, 142, 1451-1459.e1.	0.6	572
7	Epidemiology and Natural History of Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2018, 154, 319-332.e3.	0.6	472
8	Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 313-319.	0.5	438
9	ACG Practice Guidelines: Esophageal Reflux Testing. <i>American Journal of Gastroenterology</i> , 2007, 102, 668-685.	0.2	323
10	Mechanical Properties of the Esophagus in Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2011, 140, 82-90.	0.6	314
11	Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 111-122.e10.	0.6	300
12	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.4	288
13	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. <i>Cut</i> , 2016, 65, 524-531.	6.1	279
14	Esophageal Dilatation in Eosinophilic Esophagitis: Effectiveness, Safety, and Impact on the Underlying Inflammation. <i>American Journal of Gastroenterology</i> , 2010, 105, 1062-1070.	0.2	277
15	Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 500-507.	1.5	253
16	Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2016, 150, 581-590.e4.	0.6	251
17	American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. <i>Gastroenterology</i> , 2015, 149, 1944-1949.	0.6	249
18	Esophageal Distensibility as a Measure of Disease Severity in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1101-1107.e1.	2.4	248

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 147, 1255-1266.e21.	0.6	221
20	Pediatric and adult eosinophilic esophagitis: similarities and differences. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 477-490.	2.7	212
21	Esophagogastric junction distensibility assessed with an endoscopic functional luminal imaging probe (EndoFLIP). <i>Gastrointestinal Endoscopy</i> , 2010, 72, 272-278.	0.5	211
22	AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 1776-1786.	0.6	188
23	RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2019, 156, 592-603.e10.	0.6	182
24	Evaluation of Esophageal Motility Utilizing the Functional Lumen Imaging Probe. <i>American Journal of Gastroenterology</i> , 2016, 111, 1726-1735.	0.2	181
25	American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. <i>Gastroenterology</i> , 2017, 152, 271-275.	0.6	178
26	Functional Lumen Imaging Probe for the Management of Esophageal Disorders: Expert Review From the Clinical Practice Updates Committee of the AGA Institute. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 325-334.	2.4	177
27	Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. <i>New England Journal of Medicine</i> , 2020, 383, 1624-1634.	13.9	173
28	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2017, 152, 776-786.e5.	0.6	166
29	Histopathologic Variability in Children With Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2009, 104, 716-721.	0.2	148
30	Esophagogastric junction distensibility measurements during Heller myotomy and POEM for achalasia predict postoperative symptomatic outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 522-528.	1.3	137
31	Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 477-488.	3.7	135
32	Esophageal Microbiome in Eosinophilic Esophagitis. <i>PLoS ONE</i> , 2015, 10, e0128346.	1.1	134
33	Manometric features of eosinophilic esophagitis in esophageal pressure topography. <i>Neurogastroenterology and Motility</i> , 2011, 23, 208-e111.	1.6	125
34	Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 634-642.	1.9	120
35	T-Helper 2 Cytokines, Transforming Growth Factor $\beta$ 1, and Eosinophil Products Induce Fibrogenesis and Alter Muscle Motility in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 146, 1266-1277.e9.	0.6	114
36	The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 790-798.	1.9	104

#	ARTICLE	IF	CITATIONS
37	Clinical Implications and Pathogenesis of Esophageal Remodeling in Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 297-316.	1.0	103
38	EUS and histopathologic correlates in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2001, 54, 373-377.	0.5	97
39	Temporal trends in the relative prevalence of dysphagia etiologies from 1999-2009. <i>World Journal of Gastroenterology</i> , 2012, 18, 4335.	1.4	94
40	Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1056-1063.	2.4	86
41	Four-Day Bravo pH Capsule Monitoring With and Without Proton Pump Inhibitor Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1083-1088.	2.4	84
42	Esophagogastric Junction Morphology Predicts Susceptibility to Exercise-Induced Reflux. <i>American Journal of Gastroenterology</i> , 2004, 99, 1430-1436.	0.2	82
43	Functional luminal imaging probe topography: an improved method for characterizing esophageal distensibility in eosinophilic esophagitis. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 97-107.	1.4	77
44	Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1000-1010.	1.9	76
45	Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1307-1308.e3.	1.5	74
46	Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e119.	1.3	74
47	Assessing Adherence and Barriers to Long-Term Elimination Diet Therapy in Adults with Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1756-1762.	1.1	70
48	Effectiveness of esophageal dilation for symptomatic cricopharyngeal bar. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 148-152.	0.5	68
49	Severity of endoscopically identified esophageal rings correlates with reduced esophageal distensibility in eosinophilic esophagitis. <i>Endoscopy</i> , 2016, 48, 794-801.	1.0	68
50	Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 281-284.	0.5	68
51	Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 840-851.	0.6	67
52	Qualitative Assessment of Patient-reported Outcomes in Adults With Eosinophilic Esophagitis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 769-774.	1.1	65
53	One-Hour Esophageal String Test: A Nonendoscopic Minimally Invasive Test That Accurately Detects Disease Activity in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1614-1625.	0.2	57
54	Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 525-534.e10.	2.4	57

#	ARTICLE	IF	CITATIONS
55	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	2.4	57
56	Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 379-386.	8.2	55
57	Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 473-483.e17.	2.4	54
58	Proton pump inhibitor-“responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 631-633.	1.5	53
59	Evaluation of esophageal distensibility in eosinophilic esophagitis: an update and comparison of functional lumen imaging probe analytic methods. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1844-1853.	1.6	52
60	Association Between <i>Helicobacter pylori</i> Exposure and Decreased Odds of Eosinophilic Esophagitis—A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2185-2198.e3.	2.4	51
61	Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 666-673.e8.	2.4	51
62	Emerging therapies for eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 38-45.	1.5	51
63	Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 255-269.	1.5	51
64	Therapeutic End Points in Eosinophilic Esophagitis: Is Elimination of Esophageal Eosinophils Enough?. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 750-752.	2.4	48
65	Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. <i>Arthritis Research and Therapy</i> , 2015, 17, 194.	1.6	48
66	Working with the US Food and Drug Administration: Progress and timelines in understanding and treating patients with eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 617-619.	1.5	46
67	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 130-138.e1.	1.5	45
68	How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 402-414.	0.2	44
69	Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2024-2035.	1.1	44
70	Pathophysiology of achalasia. <i>Current Gastroenterology Reports</i> , 1999, 1, 198-202.	1.1	42
71	Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. <i>Gut</i> , 2019, 68, 2152-2160.	6.1	42
72	Esophageal Hypervigilance and Symptom-Specific Anxiety in Patients with Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2021, 161, 1133-1144.	0.6	42

#	ARTICLE	IF	CITATIONS
73	AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 416-423.	0.5	41
74	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	1.5	40
75	Dilation in eosinophilic esophagitis: to do or not to do?. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 713-714.	0.5	38
76	White Paper AGA: Drug Development for Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1173-1183.	2.4	37
77	Biological therapies for eosinophilic gastrointestinal diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 24-31.e2.	1.5	37
78	Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease - Bilitec, intraluminal impedance and Bravo capsule pH monitoring. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 12-24.	1.9	35
79	Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1011-1014.	1.5	34
80	Prospective assessment of disease-specific quality of life in adults with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.2	34
81	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	2.4	33
82	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Gastroenterology</i> , 2022, 163, 59-76.	0.6	33
83	Acid Reflux Detection and Symptom-Reflux Association Using 4-Day Wireless pH Recording Combining 48-Hour Periods Off and On PPI Therapy. <i>American Journal of Gastroenterology</i> , 2008, 103, 1631-1637.	0.2	32
84	An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 367-376.e3.	1.5	32
85	Histopathologic Variability in Children With Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2009, 104, 716-721.	0.2	31
86	Creating a multi-center rare disease consortium – the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Translational Science of Rare Diseases</i> , 2017, 2, 141-155.	1.6	30
87	Eosinophilic Esophagitis and Gastroesophageal Reflux Disease: There and Back Again. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 99-101.	2.4	29
88	Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 750-759.	1.9	29
89	Chronic Intestinal Pseudo-Obstruction. <i>Digestive Diseases</i> , 2000, 18, 83-92.	0.8	28
90	Editorial: Should Patients With Suspected Eosinophilic Esophagitis Undergo a Therapeutic Trial of Proton Pump Inhibition?. <i>American Journal of Gastroenterology</i> , 2013, 108, 373-375.	0.2	28

#	ARTICLE	IF	CITATIONS
91	Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 535-545.e15.	2.4	28
92	Medical Nutrition Therapy for Patients With Advanced Systemic Sclerosis (MNT PASS): A Pilot Intervention Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 678-684.	1.3	26
93	Diagnosis and Treatment of Eosinophilic Esophagitis in Adults. <i>American Journal of Medicine</i> , 2016, 129, 924-934.	0.6	25
94	Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration. <i>Gastroenterology</i> , 2019, 156, 838-842.	0.6	25
95	Eosinophilic gastrointestinal diseasesâ€”clinically diverse and histopathologically confounding. <i>Seminars in Immunopathology</i> , 2012, 34, 715-731.	2.8	23
96	Esophageal Dysmotility Is Associated With Disease Severity in Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1719-1728.e3.	2.4	23
97	Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1501-1509.	2.1	22
98	Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitis. <i>Journal of Gastroenterology</i> , 2020, 55, 249-260.	2.3	22
99	Foodâ€”induced immediate response of the esophagusâ€”A newly identified syndrome in patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 339-347.	2.7	22
100	Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cellâ€”Fibroblast Crosstalk. <i>Gastroenterology</i> , 2022, 162, 439-453.	0.6	22
101	Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 766-775.e4.	2.4	21
102	Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1488-1498.e11.	2.4	21
103	Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study. <i>Gastroenterology</i> , 2022, 162, 1635-1649.	0.6	21
104	Comparison of endoscopy and radiographic imaging for detection of esophageal inflammation and remodeling in adults with eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 962-968.	0.5	20
105	Therapeutic strategies in eosinophilic esophagitis: Induction, maintenance and refractory disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 829-839.	1.0	19
106	Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1842-1844.	2.4	19
107	Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1148-1157.	1.1	19
108	How to Approach a Patient With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2018, 155, 601-606.	0.6	19

#	ARTICLE	IF	CITATIONS
109	High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 524-529.	0.9	19
110	Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2514-2523.e2.	2.4	19
111	Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 699-706.e4.	2.4	19
112	Deaths after living related liver transplantation. <i>Liver Transplantation</i> , 2000, 6, 250-250.	1.3	18
113	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1126-1137.e2.	0.5	18
114	Role of Advanced Diagnostics for Eosinophilic Esophagitis. <i>Digestive Diseases</i> , 2014, 32, 78-83.	0.8	17
115	Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 28-37.	1.5	17
116	Advances in diagnostic testing for gastroesophageal reflux disease. <i>World Journal of Gastroenterology</i> , 2010, 16, 3750.	1.4	17
117	Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort. <i>American Journal of Gastroenterology</i> , 2022, 117, 413-423.	0.2	17
118	Eosinophilic esophagitis: Pathophysiology and optimal management. <i>Current Gastroenterology Reports</i> , 2009, 11, 175-181.	1.1	16
119	Long Term Maintenance Therapy With Dietary Restriction in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2011, 140, S-180-S-181.	0.6	16
120	Application of the Functional Lumen Imaging Probe to Esophageal Disorders. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 10-25.	0.3	16
121	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1477-1488.e10.	2.4	16
122	Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2485-2494.e15.	2.4	16
123	Treatment of eosinophilic esophagitis: Drugs, diet, or dilation?. <i>Current Gastroenterology Reports</i> , 2007, 9, 181-188.	1.1	15
124	Prospective assessment of the diagnostic utility of esophageal brushings in adults with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2016, 29, 48-53.	0.2	15
125	Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multicenter study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2520-2533.	2.7	15
126	Clinical outcomes of adults with eosinophilic esophagitis with severe stricture. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 44-53.	0.5	14



#	ARTICLE	IF	CITATIONS
127	Mast cell-pain connection in eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1895-1899.	2.7	14
128	2015 David Y. Graham Lecture: The First Two Decades Of Eosinophilic Esophagitis—From Acid Reflux To Food Allergy. <i>American Journal of Gastroenterology</i> , 2016, 111, 770-776.	0.2	13
129	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.2	13
130	Diet therapy for eosinophilic esophagitis. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 407-415.	1.0	12
131	Type 2 Immunity and Age Modify Gene Expression of Coronavirus-induced Disease 2019 Receptors in Eosinophilic Gastrointestinal Disorders. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 718-722.	0.9	12
132	New Technologies for the Evaluation of Esophageal Motility Disorders: Impedance, High-resolution Manometry, and Intraluminal Ultrasound. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 531-551.	1.0	11
133	Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 329-344.	1.0	11
134	A Randomized, Double-Blind, Placebo-Controlled Trial of a Fluticasone Propionate Orally Disintegrating Tablet in Adult and Adolescent Patients with Eosinophilic Esophagitis: A Phase 1/2A Safety and Tolerability Study. <i>Gastroenterology</i> , 2017, 152, S195.	0.6	11
135	Oral delivery of fluticasone powder improves esophageal eosinophilic inflammation and symptoms in adults with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.2	11
136	Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 748-755.	0.6	11
137	Emerging drugs for eosinophilic esophagitis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 353-364.	1.0	10
138	953 Safety and Efficacy of Oral Budesonide Suspension for Maintenance Therapy in Eosinophilic Esophagitis: Results From a Prospective Open-Label Study of Adolescents and Adults. <i>Gastroenterology</i> , 2016, 150, S188.	0.6	10
139	Eosinophilic Esophagitis: Etiology and Therapy. <i>Annual Review of Medicine</i> , 2021, 72, 183-197.	5.0	10
140	Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 844-853.	1.5	10
141	Development and Validation of Web-Based Tool to Predict Lamina Propria Fibrosis in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 272-279.	0.2	10
142	New Developments in the Diagnosis, Therapy, and Monitoring of Eosinophilic Esophagitis. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 15-26.	0.3	9
143	A 78-Year-Old Man With Difficulty Swallowing. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 470-474.	2.4	8
144	Spotlight: Treatment of Eosinophilic Esophagitis (EoE). <i>Gastroenterology</i> , 2020, 158, 1788.	0.6	8

#	ARTICLE	IF	CITATIONS
145	813 Oral Budesonide Suspension Significantly Improves Dysphagia and Esophageal Eosinophilia: Results From a Multicenter Randomized Double-Blind Placebo-Controlled Trial in Adolescents and Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2015, 148, S-157.	0.6	7
146	Narrow-caliber esophagus of eosinophilic esophagitis: difficult to define, resistant to remedy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1149-1150.	0.5	7
147	Future Directions in Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 111-122.	0.6	7
148	Eosinophilic Esophagitis—Emerging Epidemic or Misdiagnosed Malady?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 597-598.	2.4	6
149	Endoscopic assessment of eosinophilic esophagitis. <i>Techniques in Gastrointestinal Endoscopy</i> , 2014, 16, 20-25.	0.3	6
150	Advances in the endoscopic evaluation of eosinophilic esophagitis. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 325-331.	1.0	6
151	Sa1151 - Baseline Characteristics and Correlation Between Dysphagia and Disease Activity in Patients with Eosinophilic Esophagitis in a Randomized, Placebo-Controlled, Phase 2 Dupilumab Trial. <i>Gastroenterology</i> , 2018, 154, S-259.	0.6	6
152	Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2126-2128.e1.	2.4	6
153	Su1135 Validity, Usability, and Acceptability of the Eosinophilic Esophagitis Quality of Life Scale for Adults (EoE-QOL-A). <i>Gastroenterology</i> , 2012, 142, S-434.	0.6	5
154	How I Approach the Management of Eosinophilic Esophagitis in Adults. <i>American Journal of Gastroenterology</i> , 2017, 112, 197-199.	0.2	5
155	Low Prevalence of Extraesophageal Gastrointestinal Pathology in Patients with Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	5
156	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 33-47.	1.5	5
157	Ambulatory pH Monitoring: New Advances and Indications. <i>Gastroenterology and Hepatology</i> , 2006, 2, 835-842.	0.2	4
158	Clarifying misunderstandings and misinterpretations about proton pump inhibitor-responsive oesophageal eosinophilia. <i>Gut</i> , 2017, 66, 1173-1174.	6.1	3
159	Clinical Features at Baseline are Not Clearly Associated with Symptomatic Placebo Response in Adolescents and Adults with Eosinophilic Esophagitis During a Placebo Run-in Period of a Double-Blind, Randomized, Controlled Trial of Budesonide Oral Suspension. <i>Gastroenterology</i> , 2017, 152, S854.	0.6	3
160	Su1862 Systematic, Endoscopic Assessment Demonstrates Increased Fibrostenotic and Decreased Inflammatory Esophageal Features in Adults Compared With Children With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2013, 144, S-494.	0.6	2
161	Mo1183 PREDICTORS OF RESPONSE TO CORTICOSTEROID THERAPY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION. <i>Gastroenterology</i> , 2020, 158, S-817-S-818.	0.6	2
162	Wirksamkeit und Sicherheit der Langzeittherapie der Eosinophilen Ösophagitis mit einer neuen sich im Mund auflösenden Fluticason-Tablette (APT-1011): Ergebnisse einer internationalen randomisierten doppel-blinden Placebo-kontrollierten Phase 2b-Studie. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, .	0.2	2

#	ARTICLE	IF	CITATIONS
163	Oral Fluticasone Powder Improves Histopathology in Adults With Eosinophilic Esophagitis. American Journal of Gastroenterology, 2015, 110, S724-S725.	0.2	2
164	Editorial: expanding a narrow perspective on narrow calibre oesophagus in eosinophilic oesophagitis. Alimentary Pharmacology and Therapeutics, 2015, 41, 147-148.	1.9	1
165	Editorial: Reflux While Running: Something to Belch About. American Journal of Gastroenterology, 2016, 111, 947-948.	0.2	1
166	Editorial: oesophageal dilation in eosinophilic oesophagitisâ€”can and should, but when and how?. Alimentary Pharmacology and Therapeutics, 2017, 46, 556-557.	1.9	1
167	Endoscopic diagnosis and treatment of disorders of upper esophageal sphincter function. Techniques in Gastrointestinal Endoscopy, 2018, 20, 139-145.	0.3	1
168	Esophagus: Anatomy and Developmental and Structural Anomalies. , 0, , 152-159.		1
169	Eosinophilic esophagitis: are we just scratching the surface?. Gastroenterology and Hepatology, 2013, 9, 611-2.	0.2	1
170	The evolving role of the wireless pH capsule in evaluation of patients with GERD. Current GERD Reports, 2007, 1, 151-156.	0.1	0
171	Esophagus: anatomy and developmental and structural anomalies. , 0, , 717-739.		0
172	Eosinophilic Esophagitis. Gastroenterology Clinics of North America, 2014, 43, xv-xvi.	1.0	0
173	Eosinophilic esophagitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 699.	1.0	0
174	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1314-1315.	2.4	0
175	Contributions From Gastroenterology: Acid Peptic Disorders, Barrettâ€™s Esophagus and Eosinophilic Esophagitis. Gastroenterology, 2018, 154, 1209-1214.	0.6	0
176	Editorial: longâ€”term effectiveness of elimination diet therapy for eosinophilic oesophagitisâ€”is the glass half full or half empty?. Alimentary Pharmacology and Therapeutics, 2018, 47, 135-136.	1.9	0
177	Authorsâ€™ response. Annals of Allergy, Asthma and Immunology, 2018, 121, 747-748.	0.5	0
178	Maintenance Topical Steroid Therapy in Eosinophilic Esophagitis: Not So Hard to Swallow Any More?. Gastroenterology, 2020, 159, 1653-1655.	0.6	0
179	Editorial: fluticasone propionate orally disintegrating tabletsâ€”interesting concept but is it going anywhere? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 990-991.	1.9	0
180	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0

#	ARTICLE	IF	CITATIONS
181	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. Gastroenterology, 2021, 161, 778-784.	0.6	0
182	619 HIGH DISCOVERY RATE OF GASTRODUODENAL EOSINOPHILIA BUT NOT EOSINOPHILIC ESOPHAGITIS IN PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS. Ecological Management and Restoration, 2021, 34, .	0.2	0
183	Eosinophilic Esophagitis: Treatment Approach in Adults. , 2012, , 395-408.		0
184	An Overview of Dietary Therapies for the Treatment of Eosinophilic Esophagitis. Gastroenterology and Hepatology, 2017, 13, 381-383.	0.2	0
185	Motility Disorders of the Esophagus. , 0, , 160-177.		0